SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001347178-19-000007
Filing Date
2019-04-25
Accepted
2019-04-25 16:31:35
Documents
6
Period of Report
2019-06-13
Effectiveness Date
2019-04-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A vnda-20190613xdef14a.htm DEF 14A 1367322
2 ceo2018compcharta01.jpg GRAPHIC 108604
3 neo2018compcharta03.jpg GRAPHIC 109744
4 proxyimage1.jpg GRAPHIC 24955
5 vandaproxycardpage1.jpg GRAPHIC 239800
6 vandaproxycardpage2.jpg GRAPHIC 209565
  Complete submission text file 0001347178-19-000007.txt   2316856
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34186 | Film No.: 19767875
SIC: 2834 Pharmaceutical Preparations